These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

57 related articles for article (PubMed ID: 21661182)

  • 1. [The Shiga Microalbuminuria Reduction Trial].
    Hiroo K; Oda T; Kushiyama T; Higashi K; Yamamoto K
    Nihon Rinsho; 2010 Nov; 68 Suppl 9():445-50. PubMed ID: 21661182
    [No Abstract]   [Full Text] [Related]  

  • 2. [Type 2 diabetic patient with kidney damage. Sartans banish dialysis risk].
    MMW Fortschr Med; 2004 Jul; 146(27-28):56. PubMed ID: 15526676
    [No Abstract]   [Full Text] [Related]  

  • 3. Reduction of microalbuminuria in patients with type 2 diabetes: the Shiga Microalbuminuria Reduction Trial (SMART).
    ; Uzu T; Sawaguchi M; Maegawa H; Kashiwagi A
    Diabetes Care; 2007 Jun; 30(6):1581-3. PubMed ID: 17363751
    [No Abstract]   [Full Text] [Related]  

  • 4. Rationale and design of a study comparing two fixed-dose combination regimens to reduce albuminuria in patients with type II diabetes and hypertension.
    Bakris GL; Toto RD; McCullough PA
    J Hum Hypertens; 2005 Feb; 19(2):139-44. PubMed ID: 15457206
    [TBL] [Abstract][Full Text] [Related]  

  • 5. [Risk oriented therapy of hypertension. Lowering blood pressure and risk].
    MMW Fortschr Med; 2007 Nov; 149(46):53. PubMed ID: 18069196
    [No Abstract]   [Full Text] [Related]  

  • 6. Effects of valsartan compared to amlodipine on preventing type 2 diabetes in high-risk hypertensive patients: the VALUE trial.
    Kjeldsen SE; Julius S; Mancia G; McInnes GT; Hua T; Weber MA; Coca A; Ekman S; Girerd X; Jamerson K; Larochelle P; MacDonald TM; Schmieder RE; Schork MA; Stolt P; Viskoper R; Widimský J; Zanchetti A;
    J Hypertens; 2006 Jul; 24(7):1405-12. PubMed ID: 16794491
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Risk of diabetes in a real-world setting among patients initiating antihypertensive therapy with valsartan or amlodipine.
    Weycker D; Edelsberg J; Vincze G; Kjeldsen SE; Jamerson K; Khan ZM; Oster G
    J Hum Hypertens; 2007 May; 21(5):374-80. PubMed ID: 17314999
    [TBL] [Abstract][Full Text] [Related]  

  • 8. [VALUE study underscores the importance of reaching goal blood pressure values for minimization of cardiovascular risks].
    Praxis (Bern 1994); 2004 Oct; 93(44):1836. PubMed ID: 15559910
    [No Abstract]   [Full Text] [Related]  

  • 9. [VALUE study underscores the significance of reaching aimed blood pressure values for minimizing cardiovascular risks].
    Praxis (Bern 1994); 2004 Oct; 93(42):1748. PubMed ID: 15529964
    [No Abstract]   [Full Text] [Related]  

  • 10. Progressive effects of valsartan compared with amlodipine in prevention of diabetes according to categories of diabetogenic risk in hypertensive patients: the VALUE trial.
    Kjeldsen SE; McInnes GT; Mancia G; Hua TA; Julius S; Weber MA; Coca A; Girerd X; Jamerson K; Larochelle P; Macdonald T; Schmieder RE; Anthony Schork M; Viskoper R; Widimsky J; Zanchetti A
    Blood Press; 2008; 17(3):170-7. PubMed ID: 18608200
    [TBL] [Abstract][Full Text] [Related]  

  • 11. [VALUE].
    Okura T; Higaki J
    Nihon Rinsho; 2006 Aug; 64 Suppl 6():419-24. PubMed ID: 16981573
    [No Abstract]   [Full Text] [Related]  

  • 12. Effect of intensive blood pressure control with valsartan on urinary albumin excretion in normotensive patients with type 2 diabetes.
    Estacio RO; Coll JR; Tran ZV; Schrier RW
    Am J Hypertens; 2006 Dec; 19(12):1241-8. PubMed ID: 17161769
    [TBL] [Abstract][Full Text] [Related]  

  • 13. [Control of systolic blood pressure in the VALUE trial after 12 months].
    Schmieder RE; Handrock R;
    Dtsch Med Wochenschr; 2003 Mar; 128(10):485-6. PubMed ID: 12627338
    [No Abstract]   [Full Text] [Related]  

  • 14. Comparative evaluation of effect of valsartan/amlodipine and atenolol/amlodipine combinations on atrial fibrillation recurrence in hypertensive patients with type 2 diabetes mellitus.
    Fogari R; Zoppi A; Mugellini A; Corradi L; Lazzari P; Preti P; Derosa G
    J Cardiovasc Pharmacol; 2008 Mar; 51(3):217-22. PubMed ID: 18356684
    [TBL] [Abstract][Full Text] [Related]  

  • 15. [Antihypertensive treatment in type II diabetes and diabetic nephropathy].
    Chantrel F; Bouiller M; Kolb I; Hannedouche T
    Nephrologie; 2000; 21(2):47-55. PubMed ID: 10798204
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Predictors of new-onset diabetes mellitus in hypertensive patients: the VALUE trial.
    Aksnes TA; Kjeldsen SE; Rostrup M; Störset O; Hua TA; Julius S
    J Hum Hypertens; 2008 Aug; 22(8):520-7. PubMed ID: 18509347
    [TBL] [Abstract][Full Text] [Related]  

  • 17. [Prospective treatment study of irbesartan. Diabetic kidneys regain function].
    Lehnert H; Bramlage P; Pittrow D; Kirch W
    MMW Fortschr Med; 2003 Oct; 145(41):41. PubMed ID: 14655481
    [No Abstract]   [Full Text] [Related]  

  • 18. Cilostazol reduces microalbuminuria in type 2 diabetic nephropathy.
    Jiao XM; Jiao XJ; Zhang XG; Xu XP; Wu JX; Yao L; Zhao J; Lü XF
    Chin Med J (Engl); 2013 Nov; 126(22):4395-6. PubMed ID: 24238537
    [No Abstract]   [Full Text] [Related]  

  • 19. Kidney function during and after withdrawal of long-term irbesartan treatment in patients with type 2 diabetes and microalbuminuria: response to Andersen, Brochner-Mortensen, and Parving.
    Kaiser T; Florack C; Sawicki PT
    Diabetes Care; 2004 Jun; 27(6):1521; author reply 1521-2. PubMed ID: 15161820
    [No Abstract]   [Full Text] [Related]  

  • 20. Efficacy and tolerability of combination therapy with valsartan plus hydrochlorothiazide compared with amlodipine monotherapy in hypertensive patients with other cardiovascular risk factors: the VAST study.
    Ruilope LM; Malacco E; Khder Y; Kandra A; Bönner G; Heintz D
    Clin Ther; 2005 May; 27(5):578-87. PubMed ID: 15978306
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 3.